Inactive Instrument

Press Releases Essex Bio-Technology Limited Deutsche Boerse AG

Equities

EB51

KYG312371035

Press Releases

Unlock all the news: Be the first to know and act before the market!

Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%	03-18	AQ
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%	23-08-16	AQ
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed	23-07-26	AQ
Essex and Osteopore Entered into Exclusive Distribution Agreement	23-04-14	AQ
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore	23-04-14	AQ
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China	23-04-11	AQ
Essex Bio-Technology Announces 2022 Annual Financial Results	23-03-08	AQ
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration	23-02-22	AQ
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases	23-02-10	AQ
Essex Biotechnology Secures Exclusive Global Rights	22-10-14	AQ
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech	22-10-13	AQ
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022"	22-08-15	AQ
Essex Bio-Technology Announces 2021 Financial Results	22-03-22	AQ
Essex Bio Technology : NEXT DAY DISCLOSURE RETURN	21-08-17	PU
Essex Bio Technology : 2020 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT	21-05-06	PU
Essex Bio Technology : VOLUNTARY ANNOUNCEMENT FURTHER UPDATE IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION	21-04-20	PU
Essex Bio Technology : INSIDE INFORMATION APPROVAL TO COMMERCIALISE PRESERVATIVE-FREE UNIT-DOSE MOXIFLOXACIN HYDROCHLORIDE EYE DROPS IN THE PRC	21-04-07	PU
Essex Bio Technology : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 12 MAY 2021 (or any adjournment thereof)	21-03-25	PU
Essex Bio Technology : PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	21-03-25	PU
Essex Bio Technology : VOLUNTARY ANNOUNCEMENT FURTHER UPDATE IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION	21-03-19	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Essex Bio-Technology Limited Deutsche Boerse AG

Equities

EB51

KYG312371035

Press Releases

Filters